What is HC Wainwright’s Estimate for LXRX Q2 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Investment analysts at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for Lexicon Pharmaceuticals in a report issued on Wednesday, May 14th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.08) per share for the quarter, up from their prior forecast of ($0.09). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.10 EPS, FY2025 earnings at ($0.33) EPS and FY2026 earnings at ($0.34) EPS.

A number of other research analysts also recently issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. StockNews.com initiated coverage on Lexicon Pharmaceuticals in a report on Monday, April 21st. They issued a “sell” rating for the company. Leerink Partnrs downgraded Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Piper Sandler decreased their price target on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Finally, Leerink Partners reissued a “market perform” rating and issued a $1.00 price target (down from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $3.67.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ LXRX opened at $0.54 on Friday. The business’s 50 day moving average price is $0.53 and its 200 day moving average price is $0.71. The firm has a market cap of $193.47 million, a P/E ratio of -0.71 and a beta of 1.07. Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.45. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. The firm had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.26 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Straight Path Wealth Management acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $29,000. Bayesian Capital Management LP acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $31,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $32,000. RPO LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $33,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $38,000. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.